Chevy Chase Trust Holdings LLC lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 5.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 156,889 shares of the medical instruments supplier's stock after selling 8,657 shares during the quarter. Chevy Chase Trust Holdings LLC owned about 0.05% of Becton, Dickinson and Company worth $35,937,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the stock. Hillsdale Investment Management Inc. raised its stake in Becton, Dickinson and Company by 1.7% in the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier's stock valued at $694,000 after purchasing an additional 50 shares during the last quarter. Alpha Omega Wealth Management LLC raised its position in shares of Becton, Dickinson and Company by 5.7% in the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock valued at $225,000 after buying an additional 53 shares during the last quarter. Brady Family Wealth LLC lifted its stake in shares of Becton, Dickinson and Company by 1.2% during the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock valued at $989,000 after buying an additional 53 shares during the period. Picton Mahoney Asset Management boosted its position in Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after acquiring an additional 54 shares during the last quarter. Finally, REAP Financial Group LLC raised its holdings in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.
Becton, Dickinson and Company Stock Down 0.9%
Becton, Dickinson and Company stock traded down $1.55 during trading on Thursday, reaching $169.36. 418,770 shares of the company's stock were exchanged, compared to its average volume of 2,557,367. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The firm has a market cap of $48.54 billion, a price-to-earnings ratio of 32.31, a PEG ratio of 1.30 and a beta of 0.25. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. The company's 50-day moving average is $177.66 and its two-hundred day moving average is $210.22.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping the consensus estimate of $3.28 by $0.07. The firm had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. Becton, Dickinson and Company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.17 EPS. On average, analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.46%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's payout ratio is 79.39%.
Insider Activity at Becton, Dickinson and Company
In related news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the sale, the executive vice president now owns 4,575 shares of the company's stock, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the sale, the executive vice president now directly owns 4,887 shares in the company, valued at $964,107.36. This represents a 8.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on the company. Bank of America cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective on the stock. in a report on Thursday, May 1st. Wells Fargo & Company lowered Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research note on Thursday, May 1st. Barclays lowered their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Finally, Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and lowered their target price for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of "Hold" and a consensus target price of $219.22.
Read Our Latest Stock Report on Becton, Dickinson and Company
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
